about
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinomaLiver transplantation for viral hepatitis in 2015Neoplastic disease after liver transplantation: Focus on de novo neoplasmsAcute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statementRethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertensionTherapeutic approaches for portal biliopathy: A systematic reviewMarkers of acute rejection and graft acceptance in liver transplantationPractical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group.Who fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study.Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.Bax inhibitor-1 down-regulation in the progression of chronic liver diseases.A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.New insights into the coagulopathy of liver disease and liver transplantationSystemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury.Combined liver-kidney transplantation in a 15-year-old boy with alpha1-antitrypsin deficiency.Physical activity in solid organ transplant recipients: organizational aspects and preliminary results of the Italian project.A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3).Therapeutic application of stem cells in gastroenterology: an up-date.Histology predicts cirrhotic evolution of post transplant hepatitis CLiver transplantation in alcoholic patients.Is osteoporosis a peculiar association with primary biliary cirrhosis?Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.Should donors and recipients be matched in liver transplantation?Prophylaxis and treatment of hepatitis B in immunocompromised patients.Quality of life following organ transplantation.Experimental hepatology applied to stem cells.Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma.Report of the Paris consensus meeting on expanded criteria donors in liver transplantation.Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review.Management of hepatitis C virus infection recurrence after liver transplantation: an overview.Adherence in liver transplant recipients.Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis.Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review.Management of infections in cirrhotic patients: report of a consensus conference.Liver abnormalities and endocrine diseases.Management of infections pre- and post-liver transplantation: report of an AISF consensus conference.Sorafenib use in the transplant setting.Hepatitis C virus infection in end-stage renal disease and kidney transplantation.Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.Hepatitis C virus and liver transplantation: where do we stand?
P50
Q24540058-7844FA27-A135-45C6-B49C-2046053D203BQ26773224-7D523026-0A47-41BF-84C3-E2A8474A8B07Q26798306-814B3BEA-40F9-4271-8A72-C794061B3B78Q26864487-400C0899-2A93-41A8-AD49-83A02CCAA0B5Q28069136-6804DABA-35F3-4983-949E-F9A71BC4785FQ28073479-D72B6912-C573-46A4-9140-5EFD0C2DEEA8Q28088272-C8A39CC7-6BD3-4157-B763-26746FCEBB82Q30235146-18B5195D-8FD1-449A-AED5-78543AE048BBQ30636652-506CBC22-E425-43B8-998A-DB285D82BDC2Q33514014-94F4D7D6-730A-4B35-B30A-68161000C536Q33548519-C7C7E71C-F950-4BD3-9BDF-BE6D33E14AD9Q33575450-B1DFDC92-8CF6-4A5F-98C4-F2489DEA12AFQ33866656-B2FFD8D8-2673-46B6-98F8-1EA0C4EDA873Q34334408-5E81371B-5A2B-4327-AAFB-5D888B247B5DQ34594158-77CD928C-19E3-481B-967C-C3896296CB21Q35268217-098FA14B-100D-42EC-A640-0A7F279AB560Q35308989-02D9EB39-931A-4506-A311-012FDA7CBBA4Q35404189-4C94FDBF-E220-4820-8EC3-B63FB773B75EQ35594584-6DF3D8E4-29C7-476B-A4B2-19ACF9AF2788Q36093390-9521CB6D-FE73-478D-BBCD-B4B6E9D88AA0Q36213979-1C28A8DD-D9C5-4F5A-80D4-65E30C7D5A09Q36381360-33C9F0A0-B5E1-4A03-A891-808E92D6B590Q36571336-CF938E05-9EA9-4674-A72C-84B630D2FBC8Q36768889-5415A075-5056-4954-AB0D-2AC94E6DD017Q36777920-AA682A04-9086-4B5A-B0F1-7449928C2E27Q36998753-D7D721EF-95D9-438B-A632-89E8C12BA68DQ37028389-7E71E17F-D5D9-4B50-9FBC-4EDCCBBD0453Q37331902-97765417-5892-4007-9F56-8268638D0395Q37778561-323CBF2C-CAC0-4E08-BEBA-CAB6AC640D56Q37844982-23FEA840-A5BA-4694-9207-4C990226F917Q37850768-0E13C8D5-B927-4CF8-8500-7C321DFB5F51Q38021826-D688A2C1-9694-42BF-A1FC-163A97F2B34CQ38057976-201ED424-9C8E-4440-A81A-D879FE016B70Q38135971-3793391B-70F1-43D8-88BE-2872D696AA07Q38148867-0D6D0BF3-9ED2-484C-AE0D-93BBD6D50D3EQ38175238-028D0EE3-C56E-44A3-93F0-10A068865B84Q38210270-D8AA01B2-2FD8-41AF-A577-3733E21D3548Q38213956-D997D3C2-B084-400A-BCE3-578A1A676A63Q38221424-D112A243-2797-4A2D-85F7-0E5F93198D05Q38551818-DE0E10E2-42E2-4840-96AC-412D16314A9E
P50
description
Italiaans onderzoeker
@nl
forsker
@nb
researcher
@en
հետազոտող
@hy
name
P. Burra
@ast
P. Burra
@nl
P. Burra
@sl
Patrizia Burra
@en
Patrizia Burra
@es
Patrizia Burra
@nb
Patrizia Burra
@sq
type
label
P. Burra
@ast
P. Burra
@nl
P. Burra
@sl
Patrizia Burra
@en
Patrizia Burra
@es
Patrizia Burra
@nb
Patrizia Burra
@sq
altLabel
P. Burra
@en
prefLabel
P. Burra
@ast
P. Burra
@nl
P. Burra
@sl
Patrizia Burra
@en
Patrizia Burra
@es
Patrizia Burra
@nb
Patrizia Burra
@sq
P106
P1153
7005916237
P27
P31
P496
0000-0002-8791-191X